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Abstract   
Oncology follow-up has traditionally prioritised disease surveillance and the assessment 
and management of symptoms associated with cancer and its treatment. Over the past 
decade the focus on late effects of radiotherapy has increased, particularly those that limit 
treatment delivery and have an adverse effect on long-term function and quality of life.  
The aim of this research was to explore factors that influence the identification of 
treatment-induced female sexual difficulties in routine oncology follow-up after radical 
pelvic radiotherapy.  
A mixed methods approach was used to observe 69 radiotherapy follow-up consultations 
over a 5 month period. Results suggest that physical toxicity assessment focused on bowel 
(81%) and bladder (70%) symptoms. Vaginal toxicity was discussed less frequently (42%) 
and sexual issues explored in only 25% of consultations. Formal recording of radiation 
toxicity through assessment questionnaires was limited to patients participating in clinical 
trials. Surveillance activity and the management of active physical symptoms predominated 
and psychosocial issues were addressed in only 42% of consultations. 
Female sexual morbidity after pelvic radiotherapy remains a neglected aspect of routine 
follow-up and cancer survivorship. Developments in both individual practice and service 
provision are necessary if the identification and management of treatment-induced female 
sexual difficulties is to be improved.   
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INTRODUCTION 
Assessment of treatment late effects has received considerable attention over the last decade 
thus acknowledging the increased numbers of people living with their adverse impact 
(Creutzberg et al, 2000; Rowland et al, 2006; Barker et al, 2009; Ganz, 2009). There are 
approximately 1.8 million people in the UK recognised as cancer survivors  (DH 2010, 
2011) and an estimated 1in 10 women living with a cancer diagnosis have been treated 
for a gynecological malignancy (Forman et al 2003). 
Evaluating morbidity associated with cancer treatment has relied predominantly 
on clinician reports and observer data and late effects in particular have tended to be 
under-recognised and under-reported (Davidson & Faithfull, 2006; Andreyev et al, 
2010). Furthermore, the time course and slow trajectory of onset for many radiotherapy 
late effects (months to years) may further impede their recognition and treatment by 
clinicians (Rowland et al, 2006; Barker et al, 2009; Ganz, 2009). Recent advances in 
morbidity assessment within oncology include the use of patient reported outcome 
measures (PROMs) to improve patient experience and continuity of care (Velikova et 
al, 2010). From a clinician perspective, recognizing specific late effects may be 
influenced by a range of factors including experience, training, time constraints and 
whether or not interventions are readily available for the problem(s) identified (Murphy, 
2009). Accurate assessment and recognition are therefore the first steps in appropriately 
managing adverse effects.  
There is a now a growing realization from policy makers, clinicians and patient groups 
that the assessment and management of treatment consequences must be more 
effectively addressed through innovation in both research and service delivery (Maher 
& Denton, 2008; Macmillan, 2008; Andreyev et al, 2010; DH 2010 & 2011).  
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Each year in the UK approximately 17,000 people receive pelvic radiotherapy for the 
treatment of gynaecological, ano-rectal, bladder or prostate cancer (West and Davidson, 
2009). Treatment late effects related to the dose distribution of pelvic radiotherapy can 
have a negative impact on quality of life for at least 2 years after acute radiation effects 
have diminished (Barker et al 2009).  
Pelvic radiotherapy is associated with bowel and bladder toxicity, loss of fertility, 
vaginal and sexual changes. Yet while radiation induced bowel and bladder toxicity are 
commonly reported, detail of radiotherapy-induced female sexual morbidity is often 
more limited (Maher & Denton, 2008; Barker et al, 2009).  
 Estimates of the prevalence of female sexual difficulties after pelvic radiotherapy vary 
markedly depending on problem definition, scope and validity of research instruments 
used. Studies of sexual difficulties associated with radiotherapy for cervical cancer 
indicate prevalence rates of between 30-80% (Flay & Mathews, 1995; Bergmark et al. 
1999; Jensen et al. 2003; Davidson et al. 2003; Vistad et al. 2006). Furthermore, despite 
a plethora of patient-rated QOL studies in long-term survivors of cervical cancer (Vistad 
et al. 2006) there remains a paucity of good quality research exploring the sexual 
recovery of women after endometrial, bladder, rectal or anal cancer.  
Sexual well-being is acknowledged as a core aspect of quality of life for people 
affected by cancer, particularly those receiving treatment for pelvic malignancies (Flay 
& Mathews, 1995; Wenzel et al. 2005; Vistad et al. 2006; Foster et al. 2009). Physical 
effects include vaginal dryness, fibrosis, stenosis or shortening, vaginal bleeding and 
discharge, menopausal symptoms, skin reactions, urinary difficulties, disruption to 
bowel function and infertility (Jeffries et al 2006; Maher and Denton, 2008). While 
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common psychological responses include anxiety, depression, fear of sexual pain and 
altered femininity.  
Findings from recent radiotherapy morbidity studies appear to indicate that women 
receiving primary or adjuvant pelvic radiotherapy experience greater and more 
prolonged disruption to their sexual well being (Jensen et al. 2003; Davidson et al. 
2003) than women after surgery alone (Leake et al. 2001; Juraskova et al. 2003).  
Yet despite increasing evidence of the organic basis for female sexual morbidity 
after pelvic radiotherapy, the assessment and management of treatment-induced sexual 
difficulties remains frequently overlooked in routine cancer follow-up. Health 
professionals experience difficulty discussing sexual aspects of treatment (Jensen et al, 
2003; Stead et al, 2003) resulting in ongoing distress for women even when physical 
problem(s) have diminished.  
The first step towards being able to treat and manage the consequences of cancer 
treatment is clinical assessment (Richardson et al, 2006); without knowing the 
prevalence of symptoms and problems it remains difficult to effectively identify and 
meet patient need. Hence the principal aim of this study was to explore the factors that 
influence the assessment of female sexual difficulties as a treatment consequence within 
routine oncology follow-up.  
 
MATERIALS & METHODS 
We report results from observation of follow-up clinics with health professionals, 
patients and partners. In-depth interviews explored factors that influence the discussion 
of sexual morbidity in oncology consultations and these are reported elsewhere. 
Structured observation of radiotherapy outpatient clinics allowed the nature and content 
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of assessment undertaken by clinicians to be described and the reality of medical 
follow-up practice to be analysed. 
Observation data was collected from three gynaecological and two colorectal 
radiotherapy clinics within two South of England cancer centres. Consultations with 
women who had a diagnosis of cervical, endometrial anal or rectal cancer treated by 
radical pelvic radiotherapy from six weeks to two years previously, attending routine 
medical follow-up, met study inclusion criteria and were invited to take part in the 
study. A specific clinician was shadowed for the clinic duration in order to minimise the 
researcher’s influence on routine clinic processes. A total of 141 individual 
consultations from 31 separate gynaecological and colorectal radiotherapy clinic 
sessions were observed over a 5 month period, incorporating patients at different 
management stages post diagnosis. Seventy-two (51.06%) consultations were 
subsequently excluded from data analysis as they did not meet study entry criteria (male 
patients, excluded primary diagnoses / treatments). 
Approval for the study was obtained from the Local Research Ethics and 
Research & Development committees of both NHS Trusts. Patients and health 
professionals in outpatient consultations gave verbal consent to participate in the 
observation element of the study. Study information sheets were given to patients in 
advance of their appointment time to ensure they felt able to give informed consent for 
the researcher to be present during their consultation. No patients refused to take part in 
the study but the researcher was asked to remain outside the consultation room on four 
occasions where their presence was considered inappropriate, e.g. breaking bad news. 
As it was important to observe normal practice during consultations, the specific 
topic of the study remained covert in order not to influence patient led discussions or 
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agenda setting. Medical staff conducting follow-up were, however, aware of the study 
topic in advance of granting permission for the researcher to be present. 
An observation schedule enabled rapid recording of patient demographics, topics 
discussed and identification of the initiator of each topic.  Topics included: bowel, 
bladder and vaginal toxicity, skin reactions, pain, other symptoms, medication, test 
results, future treatment and follow-up plans, psychosocial issues and sexual issues. 
Data analysis was undertaken using SPSS (v.14) to explore the frequency and 
range of topics discussed and to identify any relationship between topic prevalence and 
participant demographics. Pearson’s Chi-Square test was used to explore the 
relationship between sets of categorical data in a series of contingency tables. The  ² 
statistic, Fisher’s Exact Test, degrees of freedom (df) and significance values were 
reported for each variable comparison conducted.  
 
RESULTS 
Data analysis was based on 69 (48.94%) observed consultations with women who met 
study entry criteria. Medical staff conducting follow-up included five consultants, five 
specialist registrars and one clinical research fellow, four of whom were male.  
A summary of the demographic details of patients participating  in observed 
consultations is presented in Table 1. The majority of women (n = 50 / 72.5%) had a 
diagnosis of cervical or endometrial cancer and were aged over 60 years (n = 37 / 
53.6%). The sample included women with both early (n = 29 / 43.3% clinical stage I / 
II) and late stage (n = 38 / 56.7% clinical stage III / IV) disease who had received 
radical radiotherapy in the management of their illness.   Consultations at different time 
points in the women’s follow-up period were also sampled.  
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The majority of women had a current partner (n = 48 / 69.6%) although details of 
relationship status were missing for seven (10.1%) women. Relationship details were 
taken from the women’s medical records and all women were noted as being in a 
heterosexual relationship.  
The most frequently discussed consultation topics related to the impact of pelvic 
radiotherapy on both bowel and bladder function in 81% (n = 56) and 70% (n = 48) of 
consultations respectively (figure 1). However, no formal method of toxicity recording 
was used by practitioners unless the woman was enrolled in a clinical trial where 
toxicity data sheets were used (six women with anal or rectal cancer / 8.7% of total 
observed consultations).  
There were 60 other topics discussed, the majority of which were physical side effects 
of treatment ranging from anorexia,  nausea, dietary intake or weight gain, to concerns 
about fatigue, general weakness, lymphoedema and continence management in 39 / 69 
(57%) of the consultations.  
 Psychological or social aspects of the women’s illness and treatment were 
discussed in 42% (n = 29) of the consultations and varied from in-depth discussion of 
the impact of disease recurrence to brief enquiries as to whether or not the woman had 
returned to work following treatment completion.  
Health care professionals were dominant in leading discussions for all of the 13 topics 
summarised in figure 1, with women initiating topic discussions with their treatment 
team in fewer than 14.5% of consultations. 
Discussion of Vaginal Toxicity 
Radiotherapy-induced vaginal toxicity was discussed in 29 (42%) of the consultations 
observed. Vaginal symptoms were either elicited by verbal questioning or through 
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vaginal examination. Vaginal examination was a routine aspect of medical review in the 
gynaecological clinics, but performed only when clinically indicated by reports of 
vaginal symptoms in the colorectal clinics.  
Vaginal bleeding was the symptom most commonly raised in 17 consultations 
by both clinicians (n = 13 / 18.8%) and women (n = 4 / 5.8%).  Despite the prominence 
of vaginal stenosis, vaginal shortening and vaginal dryness in the biomedical literature 
as common toxicities after pelvic radiotherapy, these vaginal symptoms were only 
discussed in 11 (15.9%), nine (13%) and six (7.2%) observed consultations respectively. 
Manifestations of radiation induced vaginal changes such as telangectasia or ulceration 
were normally discussed with women only when they resulted in vaginal bleeding, 
otherwise they were simply noted in patient’s records 
There was no statistically significant relationship between the discussion of 
vaginal symptoms and the time elapsed since women had completed their radiotherapy 
treatment. Vaginal symptoms were prevalent in 10 / 31 (32.2%) women who were less 
than 6 months post-treatment, in 5 / 9 (55.5%) women who had completed treatment 6-
11 months previously and in 14 / 29 (48.2%) women at 12 months or more post-
treatment.  
The provision of vaginal dilators as a prophylactic intervention to reduce the 
likelihood of developing vaginal stenosis and shortening associated with pelvic 
radiotherapy was standard practice at both research sites (Miles & Johnson, 2010). 
Despite routine dilator provision, discussion of vaginal dilator use was absent from the 
majority (n = 53 / 76.8%) of medical consultations observed.  There was, however, a 
statistically significant association (  ² = 22.870, df = 1, p = 0.000) between the 
elicitation of vaginal toxicity in consultations and a subsequent discussion of the use of 
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dilators. In only one consultation out of 15 was there a discussion of dilator provision 
where vaginal toxicity had not been identified during the consultation.  
Discussion of treatment induced menopause and its management was a topic discussed 
in nine (13%) consultations, raised predominantly by clinicians (n = 7 / 10.1%). While 
this frequency was low it was noted that in 37 / 69 (53.6%) consultations the woman 
was naturally post-menopausal at the time of her treatment, resulting in omission of this 
topic within 23 (33.3%) consultations where the woman had experienced a treatment-
induced menopause.   
 Referrals resulting from discussions of vaginal toxicity, menopause or 
sexual issues were uncommon, occurring in only eight out of 69 (11.6%) consultations. 
Women were referred to the radiotherapy nursing service on seven (10.1%) occasions, a 
clinical nurse specialist in gynae-oncology on one (1.4%) and to a patient’s GP on one 
(1.4%) occasion. 
 
Discussion of Treatment Induced Sexual Issues 
Enquiry about a woman’s sexual recovery was normally introduced by clinicians asking 
a direct question such as: “Are you sexually active at present?”  
As can be seen in Figure 2, sexual issues were discussed in a total of 17 (24.6%) 
consultations, with health care professionals raising this topic on 11 (15.9%) occasions 
and women on a further six (8.7%) occasions. The range of sexual topics discussed 
during consultations between women and their treatment team was limited, with low 
sexual desire (n = 7 / 10.1%) and reduced frequency of intercourse (n = 5 / 7.2%) 
featuring more often than discussion of dyspareunia (n = 4 / 5.8%).  
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Changes in orgasm were not discussed, nor was there any enquiry as to whether or not 
treatment had influenced women’s level of sexual satisfaction. Concerns relating to 
partner adjustment to changes in the couple’s sexual relationship associated with the 
woman’s cancer treatment were raised by two (2.9%) of the women. Discussion of 
sexual issues normally focused on treatment induced changes to women’s sexual 
function without reference to her sexual relationship other than to ascertain the presence 
or absence of a current partner.  
The age of women appeared to influence clinician’s behaviour independently of 
other factors. The majority of women (n = 21 / 69, 30.4%) fell into the 61 - 70 years age 
group, with a range from 31 to over 80 years of age. For comparative analysis age 
categories were collapsed to women > 60 years versus those 60 years or younger. 
Sexual issues were more likely to be discussed with women who were younger than 60 
years of age (13/32 consultations) compared to those older than 60 years of age (4/37 
consultations) regardless of their diagnosis or the time elapsed post-treatment (  ² = 
8.215, df = 1, p = 0.004; Fisher’s Exact test (1-sided) p = 0.005). 
Another factor that appeared influential in determining whether or not sexual issues 
were discussed in the clinical setting was the clinical stage of the patient’s illness. 
Women with stage I / II disease (11/29; 37.9%) were more likely to have discussion of 
sexual concerns with their doctor than women with clinical stage III / IV disease (6/38; 
15.7%). The difference in these two groups was statistically significant (*  ² = 4.258, 
df = 1, p = 0.039, Fisher’s Exact test (1-sided) p = 0.038) at the five per cent level. 
Changed life priorities associated with advanced cancer has the potential to influence 
patient, partner and health professional’s motivation for and comfort in discussion of 
sexual concerns (Hordern & Street, 2007). 
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DISCUSSION 
The aim of this study was to elicit the factors that influence the frequency and extent of 
enquiry about the sexual consequences of pelvic radiotherapy in routine follow-up 
consultations with women post pelvic radiotherapy. Consistent with findings from 
published studies, standardised assessment instruments for acute radiation toxicity and 
late effects recording were not in routine use at either research site (Davidson et al. 
2002; Davidson et al. 2003; Dische & Saunders, 2003). As can be seen from Figure 1, 
bowel and bladder toxicity were assessed during the majority of consultations (81% and 
70% of consultations respectively) compared to only 42% of consultations where 
vaginal toxicity was discussed. These findings are similar to audit data from Denton et 
al. (2000) whereby assessment focused on urological and bowel toxicity as late effects 
after radical radiotherapy for carcinoma of the cervix, with the relative neglect of 
vaginal toxicity and sexual morbidity.  
 
In this study the dominant topics discussed were treatment or illness related 
physical effects, future treatment and follow-up plans. Psychological and social topics 
were discussed in a minority of consultations (n = 29 / 42%), consistent with findings 
from a recent survey by Macmillan Cancer Support (2006) where 58% of respondents 
felt that cancer services addressed their emotional needs less effectively than their 
physical needs, despite 45% of respondents stating that the emotional effects of cancer 
were the most difficult to cope with.  
Discussion of the sexual consequences of pelvic radiotherapy in only 17 (24.6%) 
observed consultations must be considered low given the 50-80% estimated prevalence 
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of sexual difficulties following radiotherapy for gynaecological malignancy cited in 
published studies ( Crowther et al. 1994; Flay & Mathews 1995, Jensen et al. 2003).  
 The lack of clinical time to address psychological, social and sexual aspects of 
patient’s illness experience has been previously identified as a common reason for the 
persistent low profile of sexual rehabilitation within health care practice (Guthrie 1999; 
Gott et al. 2004). During the study period clinic volume was high and it was not 
uncommon for clinics to overrun. It could be argued that medical follow-up clinics are 
not a suitable environment for the detailed discussion or assessment of female sexual 
difficulties after cancer treatment due to time constraints, lack of privacy and a necessity 
for topic prioritisation.  
As can be seen from the data, exploration of sexual issues observed within 
oncology follow-up clinics revealed a restricted view of female sexuality, with emphasis 
predominantly on the woman’s ability to achieve vaginal intercourse (Hyde, 2007). 
Recent studies of sexual morbidity in oncology offer a more comprehensive exploration 
of the impact of treatment on all phases of the human sexual response cycle (Masters 
and Johnson 1966). These include changes in sexual interest, physiological elements of 
sexual arousal (vaginal lubrication, absence of dyspareunia) and orgasmic capacity        
( Andersen et al. 1997, Kylstra et al. 1999). The majority of these studies also explored 
whether women’s sexual satisfaction post-treatment compared favourably with their 
pre-diagnosis sexual well-being (Juraskova et al. 2003, Marijnen et al. 2005, Pieterse et 
al. 2006).   
In this study, clinician discussions focused solely on the woman, with no 
enquiry regarding the impact of sexual changes on the partner or couple. Only two 
women in observed consultations raised concerns about reduced sexual interest and 
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intercourse frequency on their partner’s sexual enjoyment. This lack of focus on the 
couple relationship in consultations mirrors findings from biomedical literature, with 
only a minority of gynaecological studies (Van De Wiel et al. 1990, DeGroot et al. 
2005) specifically exploring the sexual impact of cancer treatment on the partner or 
couple.  
Health professionals report feeling uncomfortable, and perceive patients to be 
uncomfortable, in opposite gender consultations (Burd et al. 2006). The number of 
consultations conducted by female health professionals where sexuality was discussed 
was low in this study (n = 4 / 23.5%), and participant observation does not permit 
exploration of participant’s comfort regarding the topics discussed. Hence it is not 
possible to state whether or not the prevalence and depth of discussions about sexual 
issues was influenced by clinician gender for any of these women. This was a factor 
specifically explored within this study’s interview data and is reported elsewhere.   
Burd et al. (2006) also found that doctors experienced greater “discomfort” in 
discussing sexual issues with patients who were aged over 60 years, currently without a 
partner and with lower education levels. The influence of patient age on the prevalence 
of sexual discussions was also a key finding in this study where sexual issues were more 
likely to be discussed with women who were younger than 60 years of age (13/32 
consultations) compared to those older than 60 years of age (4/37 consultations) 
regardless of their diagnosis or the time elapsed post-treatment.  
A study by Gott et al (2004) found that doctors frequently used discussion of 
contraception or reproductive health as a vehicle for broaching the more sensitive topic 
of sexual well-being among their patients. In discussions with post-menopausal women, 
where this strategy was not possible, sexual issues were less likely to be addressed. Gott 
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et al’s (2004) findings may explain the relationship between discussion of vaginal 
toxicity, vaginal dilator use and the subsequent discussion of sexual issues in 
consultations within this study. Doctors appear to find it easier to discuss vaginal 
symptoms and dilator use as a means to subsequent enquiry about sexual recovery post-
treatment as opposed to raising such sensitive topics directly.  
 The apparent reticence by many health professionals to discuss the sexual 
consequences of cancer treatment with women may also be partly explained by the lack 
of biomedical interventions developed to treat female sexual difficulties compared to 
those available for the management of erectile dysfunction (Miles et al, 2007).  
Conclusion  
Analysis of observation data from oncology clinics provides insight into the challenge 
of addressing the sexual aspects of women’s recovery after pelvic cancer in the busy 
clinical environment of routine medical follow-up. These findings suggest that in the 
two cancer centres where this research took place, the clinical assessment of female 
sexual difficulties was not a core element of routine medical follow-up after radical 
radiotherapy for women with pelvic malignancies. Women experienced a lower level of 
enquiry about their psychosocial and sexual recovery during follow-up than attention 
paid to other aspects of their physical recovery and disease surveillance.  
Clearly when considering the clinical implications of these findings, the need for 
appropriate disease surveillance and management of women’s fear of disease recurrence 
remains of paramount importance. However, traditional models of oncology follow-up 
may also mean that the provision of psychosocial and sexual aspects of recovery and 
rehabilitation frequently remain neglected.  
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Improving care for people living with and beyond cancer has received increased 
policy attention in the UK as a consequence of the launch of the National Cancer 
Survivorship Initiative (NCSI) by the Department of Health and Macmillan Cancer 
Support (2010). Development of services that improve the patient experience of cancer 
care and enhance both recovery and quality of life is also endorsed by the Department 
of Health’s latest cancer strategy focused on improving outcomes (DH, 2011, p50-51). 
To achieve improvements in the patient experience of survivorship care both documents 
endorse the need to achieve 5 key service shifts: 
• “a cultural shift in the approach to care and support for people affected by 
cancer – to a greater focus on recovery, health and well-being after cancer treatment;  
• a shift towards assessment, information provision and personalised care 
planning;  
• a shift towards support for self-management, based on individual needs and with 
the appropriate clinical assessment, support and treatment;  
• a shift from a single model of clinical follow up to tailored support that enables 
early recognition of and preparation for the consequences of treatment as well as early 
recognition of signs and symptoms of further disease;  
• a shift from an emphasis on measuring clinical activity to a new emphasis on 
measuring experience and outcomes for cancer survivors through routine use of Patient 
Reported Outcome Measures (PROMs) in aftercare services.” 
Achieving such significant cultural and organisational change in oncology is 
undoubtedly challenging, particularly within current financial constraints. However, 
developing staff to deliver new models of aftercare that are characterised by tailored 
support and personalised care pathways based on an individual’s health status, treatment 
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consequences, relationship and life priorities may lead to improved sexual rehabilitation 
for women after cancer. 
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Table 1: Patient Demographics in Observed Consultations 
Patient Demographics No. /  % 
(n = 69)  
Patient Demographics No.  /  % 
(n = 69) 
Cervical Cancer  
Endometrial Cancer 
20 (29%) 
30 (43.5%) 
Anal Cancer  
Rectal Cancer 
5   (7.2%) 
14 (20.3%) 
Clinical Stage:           I / II  
Clinical Stage:        III / IV 
29 (43.3%) 
38 (56.7%) 
Age of woman </= 60 years 
Age of woman > 60 years 
32 (46.4%) 
37 (53.6%) 
*Treatment Type:  CTRT 
                               EBBRA 
                               EBRT 
31 (44.9%) 
32 (46.4%) 
6   (8.7%) 
Time Post RT <6 months 
Time Post RT 6-11 months 
Time Post RT >/= 12 months 
31 (44.9%) 
9   (13%) 
29 (42%) 
Relationship Status:  
                           Partner 
                           No Partner 
 
48 (69.6%) 
14 (20.3%) 
Woman accompanied at 
consultation:          Yes 
                               No 
 
30 (43.5%) 
39 (56.5%) 
*Key: CTRT: Chemo-radiotherapy  
EBRT: External Beam Pelvic Radiotherapy 
           EBBRA: External beam radiotherapy & vaginal brachytherapy  
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% of consultations in which each topic arises 
(ranked by magnitude, n=69)
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Figure Captions 
 
 
Figure 1: Range of Topics Discussed during Women’s Consultations with 
Medical Staff  
 
Figure 2: Sexual Issues Discussed in Follow-up Consultations with Medical Staff  
 
